Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade.
Malignant mesothelioma (MM) is a deadly tumor mainly caused by exposure to asbestos. Unfortunately, no current treatment is able to change significantly the natural history of the disease, which has a poor prognosis in the majority of patients. The non-receptor tyrosine kinase SRC and other SRC fami...
| Publicado en: | Cancers Vol. 12; no. 7; pp. 1866 - 1867 |
|---|---|
| Autores principales: | , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
MDPI
Jul2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=144874050&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 144874050 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20726694 B74B jtl: Cancers issn: 20726694 maglogo: N pubinfo: dt: Jul2020 vid: 12 iid: 7 pid: 97109 pub: MDPI artinfo: ui: 144874050 144874050 144874050 10.3390/cancers12071866 144874050 ppf: 1866 ppct: 1 formats: tig: atl: Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade. aug: au: Indovina, Paola Forte, Iris Maria Pentimalli, Francesca Giordano, Antonio affil: Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA sug: subj: Mesothelioma, Malignant Drug Therapy Protein-Tyrosine Kinases Therapeutic Use Antineoplastic Agents Mesothelioma, Malignant Prognosis Cell Proliferation Drug Effects Survival Cell Movement Disease Progression Pathology, Molecular Cell Line, Tumor Drug Effects ab: Malignant mesothelioma (MM) is a deadly tumor mainly caused by exposure to asbestos. Unfortunately, no current treatment is able to change significantly the natural history of the disease, which has a poor prognosis in the majority of patients. The non-receptor tyrosine kinase SRC and other SRC family kinase (SFK) members are frequently hyperactivated in many cancer types, including MM. Several works have indeed suggested that SFKs underlie MM cell proliferation, survival, motility, and invasion, overall affecting multiple oncogenic pathways. Consistently, SFK inhibitors effectively counteracted MM cancerous features at the preclinical level. Dasatinib, a multi-kinase inhibitor targeting SFKs, was also assessed in clinical trials either as second-line treatment for patients with unresectable MM or, more recently, as a neoadjuvant agent in patients with resectable MM. Here, we provide an overview of the molecular mechanisms implicating SFKs in MM progression and discuss possible strategies for a more successful clinical application of SFK inhibitors. Our aim is to stimulate discussion and further consideration of these agents in better designed preclinical and clinical studies to make the most of another class of powerful antitumoral drugs, which too often are lost in translation when applied to MM. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|